EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Neurofibromatosis Type I: Consensus on Current Terminology for Neurofibromas, as a Basis for Recommendations on the Use of MEK Inhibitors

Laura Baldino, Johannes A Koeppen, Josef Kammermeier, Isabel Gugel, Inka Ristow, Christian Hagel, Jens Panse, Catena Kresbach, Reinhard E Friedrich, Said C Farschtschi, Thorsten Rosenbaum, Andreas Kurtz und 12 weitere

Anticancer Research · 2026

DOI: 10.21873/anticanres.18332 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Anticancer Research, 2026. Verfasst von Laura Baldino und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital Hamburg Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Terminology as Topic, Protein Kinase Inhibitors, Neurofibroma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofibromatosis 1Terminology as TopicProtein Kinase InhibitorsNeurofibromaHumansNeurofibroma, Plexiform

Stichwörter der Autor:innen

MEK inhibitorNeurofibromatosis 1nerve sheath tumorsplexiform neurofibromareviewterminology

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Neurology, University Hospital Hamburg Eppendorf, Hamburg, Germany.
  • Department of Neurosurgery, University Hospital Hamburg Eppendorf, Hamburg, Germany.
  • "Nothing is forever e.V.", Charitable Public-benefit Non-profit Organization, Sinzing, Germany.
  • Department of Neurosurgery and Nanotechnology, Center of Neurofibromatosis and Schwannomatosis, University Hospital Tübingen, Tübingen, Germany.
  • Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Diagnostics, Institute of Neuropathology, University Hospital Hamburg Eppendorf, Hamburg, Germany.

Zitieren

APA

Baldino, L., Koeppen, J. A., Kammermeier, J., Gugel, I., Ristow, I., Hagel, C., Panse, J., Kresbach, C., Friedrich, R. E., Farschtschi, S. C., Rosenbaum, T., Kurtz, A., Hernaiz-Driver, P., Kaufmann, D., Zenker, M., Schuhmann, M. U., Widemann, B. C., Rosahl, S. K., Alt, F., …, & Mautner, V. F. (2026). Neurofibromatosis Type I: Consensus on Current Terminology for Neurofibromas, as a Basis for Recommendations on the Use of MEK Inhibitors. Anticancer Research. https://doi.org/10.21873/anticanres.18332

Vancouver

Baldino L, Koeppen JA, Kammermeier J, Gugel I, Ristow I, Hagel C, et al. Neurofibromatosis Type I: Consensus on Current Terminology for Neurofibromas, as a Basis for Recommendations on the Use of MEK Inhibitors. Anticancer Research. 2026. doi:10.21873/anticanres.18332

BibTeX
@article{Baldino2026,
  author = {Baldino, Laura and Koeppen, Johannes A and Kammermeier, Josef and Gugel, Isabel and Ristow, Inka and Hagel, Christian and Panse, Jens and Kresbach, Catena and Friedrich, Reinhard E and Farschtschi, Said C and Rosenbaum, Thorsten and Kurtz, Andreas and Hernaiz-Driver, Pablo and Kaufmann, Dieter and Zenker, Martin and Schuhmann, Martin U and Widemann, Brigitte C and Rosahl, Steffen K and Alt, Franziska and Kehrer-Sawatzki, Hildegard and Baezner, Ute and Tippner, Daniel and Harder, Anja and Mautner, Victor-F},
  title = {Neurofibromatosis Type I: Consensus on Current Terminology for Neurofibromas, as a Basis for Recommendations on the Use of MEK Inhibitors},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18332}
}
Kostenlos starten →